{"nctId":"NCT01296412","briefTitle":"Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)","startDateStruct":{"date":"2011-03-11","type":"ACTUAL"},"conditions":["Diabetes Mellitus, Type 2"],"count":653,"armGroups":[{"label":"Sitagliptin +/- glimepiride","type":"EXPERIMENTAL","interventionNames":["Drug: sitagliptin","Drug: glimepiride","Drug: metformin"]},{"label":"Liraglutide","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: liraglutide","Drug: metformin"]}],"interventions":[{"name":"sitagliptin","otherNames":["MK-0431, Januvia®, Tesavel®, Xelevia®, Ristaben®"]},{"name":"liraglutide","otherNames":["Victoza®"]},{"name":"glimepiride","otherNames":["Amaryl®"]},{"name":"metformin","otherNames":["Fortamet®, Glucophage®, Glucophage® XR, Glumetza®, Riomet®, Metgluco®, Glycoran®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria\n\n* Type 2 diabetes mellitus.\n* On stable dose of metformin monotherapy at a dose of at least 1500 mg per day for at least 12 weeks and a hemoglobin A1C ≥7.0% and ≤11.0%.\n* Capable of using a liraglutide pen device.\n\nExclusion criteria\n\n* History of Type 1 Diabetes mellitus.\n* Use of any oral antihyperglycemic agent (AHA) besides metformin, within the prior 12 weeks of screening.\n* Cardiovascular disorders within the past 3 months including acute coronary syndrome or new or worsening symptoms of coronary heart disease, coronary artery intervention, stroke, or transient ischemic neurological disorder.\n* Impaired liver function.\n* Impaired kidney function.\n* History of malignancy or clinically important hematological disorder that requires disease-specific treatment (chemotherapy, radiation therapy, surgery) or, in the opinion of the investigator, is likely to recur during the duration of the study.\n* History of leukemia, lymphoma, aplastic anemia, myeloproliferative or myelodysplastic diseases, thrombocytopenia, or malignant melanoma, regardless of the time since treatment.\n* Pregnancy or breastfeeding, or intention to become pregnant or donate eggs within the projected duration of the study.\n* Participation in another study with an investigational drug or device within 12 weeks prior to screening.\n* History of hypersensitivity or any contraindication to sitagliptin, liraglutide, glimepiride, or metformin based upon the labels of the country of the investigational site.\n* Participation in a weight loss program and not yet in maintenance phase, or starting of a weight loss medication (such as orlistat or phentermine) within the prior 8 weeks.\n* Surgery within the prior 4 weeks or major surgery planned during the study.\n* Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).\n* User of recreational or illicit drugs or recent history (within the last year) of drug abuse or increased alcohol consumption.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"79 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Hemoglobin A1c (A1C)","description":"A1C is measured as percent. Thus, this change from baseline reflects the Week 26 A1C percent minus the Week 0 A1C percent.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.32","spread":"1.06"},{"groupId":"OG001","value":"-1.42","spread":"1.04"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG)","description":"Change from baseline at Week 26 is defined as Week 26 minus Week 0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-33.7","spread":"46.2"},{"groupId":"OG001","value":"-39.6","spread":"40.3"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Reaching A1C Goal of <7.0%","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.8","spread":null},{"groupId":"OG001","value":"72.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Reaching A1C Goal of <6.5%","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.8","spread":null},{"groupId":"OG001","value":"38.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":17,"n":326},"commonTop":["Nausea","Hypoglycaemia","Diarrhoea","Vomiting","Decreased appetite"]}}}